New Therapies in Alzheimer's Disease

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

AD: Largest Unmet Need in Neurology

Deaths Attributable to AD in the United States

AD Progression

Hallmark of AD Pathology: Amyloid Plaques and Neurofibrillary Tangles in Brain

AD Cascade: Sequential

AD Cascade: Integrative

Existing AD Treatments

Treatment Goals

A Model of Cognitive Benefit: Galantamine

Treatment Goals Revisited

Amyloid Targets of AD Therapies

Tau Targets of AD Therapies

RAGE Inhibition: A Multifactorial Target for AD

Recent AD Phase 3 Candidate Therapies

Drugs to Delay AD Progression Have Challenges

Drugs to Delay AD Progression Have Challenges (cont)

Bapineuzumab Clears Plaques, But Fails to Show Clinical Benefit in AD

Combined EXPEDITION 1 and 2 Data in Mild and Moderate AD

Analysis of Delayed-Start Data in EXPEDITION in Mild AD

EXPEDITION 3: Study Design and Results

PRIME: Study Design and Results

PRIME: CDR-SB Data

PRIME: SUVR Data

PRIME 12-Month Interim Analysis of Titration Dosing

ARIA

LMTM in Mild AD

RVT-101 

AD Prevention

Ongoing Phase 3 RCTs in Presymptomatic AD

Ongoing Phase 3 RCTs in Presymptomatic AD (cont)

Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD

Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

Conclusions